{"id":666118,"date":"2023-09-04T19:32:01","date_gmt":"2023-09-04T19:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=666118"},"modified":"2023-09-04T19:32:01","modified_gmt":"2023-09-04T19:32:01","slug":"glomerulonephritis-market-to-expand-at-a-significant-growth-rate-during-the-forecast-period-202332-asserts-delveinsight-astrazeneca-alnylam-apellis-otsuka-visterra-chemocentryx-omeros","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/glomerulonephritis-market-to-expand-at-a-significant-growth-rate-during-the-forecast-period-202332-asserts-delveinsight-astrazeneca-alnylam-apellis-otsuka-visterra-chemocentryx-omeros_666118.html","title":{"rendered":"Glomerulonephritis Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Asserts DelveInsight | AstraZeneca, Alnylam, Apellis, Otsuka, Visterra, ChemoCentryx, Omeros"},"content":{"rendered":"
\n
\"Glomerulonephritis<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Glomerulonephritis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Glomerulonephritis and the improvement in the research and development activities so that the market will comprise efficient treatment options.<\/div>\n

DelveInsight’s “Glomerulonephritis Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Glomerulonephritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Glomerulonephritis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Glomerulonephritis treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Glomerulonephritis: An Overview<\/strong><\/p>\n

Glomerulonephritis (GN) also known as nephritis or nephrotic syndrome is a group of diseases that injure the part of the kidney that filters blood (called glomeruli). When the kidney is injured, it cannot get rid of wastes and extra fluid in the body. If the illness continues, the kidneys may stop working completely, resulting in kidney failure.<\/p>\n

There are two types of Glomerulonephritis —acute and chronic.<\/strong> The acute form develops suddenly. The chronic form may develop silently (without symptoms) over several years. It often leads to complete kidney failure. It can aslo be classified as originating in or confined primarily to the kidney (primary) and as related to systemic immunologic disorders, such as systemic lupus erythematosus (SLE) (secondary).<\/p>\n

The acute disease may be caused by infections such as strep throat. It may also be caused by other illnesses, including lupus, Goodpasture’s syndrome, Wegener’s disease, and polyarteritis nodosa. Sometimes, the disease runs in the family. This kind often shows up in young men who may also have hearing loss and vision loss. Some forms are caused by changes in the immune system. However, in many cases, the cause is not known.<\/p>\n

Glomerulonephritis often comes to light when a routine urinalysis is abnormal. Tests to assess kidney function and make a diagnosis of Glomerulonephritis include urine tests, blood tests, imaging tests, and kidney biopsies. The treatment for glomerulonephritis depends on what is causing it. Certain medicines called angiotensin-converting enzyme (ACE) inhibitors such as captopril, lisinopril, perindopril, and angiotensin receptor blockers (ARBs) such as losartan, irbesartan, valsartan can help control blood pressure.  <\/p>\n

Though there are no FDA-approved drugs for the treatment of Glomerulonephritis but many different therapies have been studied for the cure of its separate clinical features.<\/p>\n

Glomerulonephritis Market Key Facts<\/strong><\/p>\n